Brian Poligone
Chair of Cutaneous T-Cell Lymphoma Medical Advisory BoardDr. Brian Poligone, MD, PhD, is Chair of Cutaneous T-Cell Lymphoma Medical Advisory Board of Soligenix, Inc. from October 14, 2025. Dr. Poligone is the founder and Medical Director of the Rochester Skin Lymphoma Medical Group and the Director of Cancer Biology Research for the Rochester General Hospital Research Institute, where his research focuses on the underlying mechanism of skin cancers. With over 50 publications in his specialty, Dr. Poligone has been invited to speak at more than 100 meetings on both his scientific studies and clinical knowledge in the field of lymphoma and skin cancer. He has also served on a number of NIH review committees. Dr. Poligone completed his internship in Internal Medicine at Stanford University, received his MD and PhD at the University of North Carolina at Chapel Hill and trained at Yale University in the field of cutaneous lymphoma. Dr. Poligone has enrolled over 40 patients while participating in 4 clinical trials evaluating HyBryte™ photodynamic therapy. As such, has treated more patients with HyBryte than any other physician in the world.
Positions
- Company NameSoligenix, Inc.Stock CodeSNGXPositionChair of Cutaneous T-Cell Lymphoma Medical Advisory BoardColleagues
- CJChristopher J. SchaberChairman of the Board of Directors, CEO & President
- JLJonathan L. GuarinoSenior VP, CFO & Corporate Secretary
- ODOreola DoniniSenior VP & Chief Scientific Officer
- ATAdam T. RumageSenior VP of Project Management & Regulatory Affairs
- GAGregory Anthony LapointeIndependent Director
- RJRobert J. RubinIndependent Director
- JBJerome Bernard ZeldisIndependent Director
